The Potential Effect of Intravenous Calcitriol on the Ischemia-Reperfusion Injury and Inflammatory Biomarkers in Patients following Percutaneous Coronary Intervention (PCI)

Document Type : Research article

Authors

1 Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Chronic Respiratory Disease Research Center, NRTLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Department of Cardiology, Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Chronic Respiratory Disease Research Center, NRTLD, Tehran, Iran.

5 Tobacco Prevention and Control Research Center, NRTLD, Tehran, Iran.

6 Clinical Pharmacy department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Objectives: This study aimed to investigate the efficacy of calcitriol on Ischemia-reperfusion Injury (IRI) and inflammatory biomarkers in patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) undergoing elective Percutaneous Coronary Intervention (PCI).
Methods: A total of 72 patients with NSTEACS were randomly divided into two groups: (1) the calcitriol-treated group, treated with three mcg intravenous calcitriol administered before PCI (n = 36), and (2) the control-treated group (n = 36). The serum high-sensitivity C-reactive protein (hs-CRP), high-sensitivity interleukin-6 (hs-IL-6), creatinine kinase (CK)-MB and cardiac troponin I (cTnI) levels were measured before PCI and 24 hours after PCI in both groups. The patients were followed up for the detection of the prevalence of major adverse cardiac events (MACE) in 180 days after PCI in both groups.
Results: Compared to pre-PCI, the serum hs-CRP, hs-IL-6, CK-MB, and cTnI levels were increased at 24 h after PCI (all p<0.05) in both groups. However, change in the levels of hs-CRP and hs-IL-6 were significant (p=0.04 and p=0.02, respectively). Changes in the levels of CK-MB and cTnI were non-significant (p=0.15 and p=0.39, respectively).
No MACE (death, Q wave MI, target vessel revascularization, ischemic stroke) was detected in any patient in any group during a 3-month follow-up.
Conclusion: Administration of calcitriol in patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum inflammatory biomarkers in the serum (hs-CRP and hs-IL-6) and thus decrease the inflammatory reaction caused by PCI.

Keywords

Main Subjects


(1) Wang J, Tan G-J, Han L-N, Bai Y-Y, He M and
Liu H-B. Novel biomarkers for cardiovascular risk
prediction. JGC (2017) 14: 135.
(2) Jiao Y, Hu F, Zhang Z, Gong K, Sun X, Li A and Liu
N. Efficacy and safety of loading-dose rosuvastatin
therapy in elderly patients with acute coronary
syndromes undergoing elective percutaneous
coronary intervention. Clin. Drug Invest. (2015)
35: 777-84.
(3) Wang J-N, Yan Y-Y, Guo Z-Y, Jiang Y-J, Liu L-L
and Liu B. Negative association of circulating
microRNA-126 with high-sensitive C-reactive
protein and vascular cell adhesion molecule-1 in
patients with coronary artery disease following
percutaneous coronary intervention. Chin. Med. J.
(2016) 129: 2786.
(4) Thygesen K, Alpert JS and White HD. Universal
definition of myocardial infarction. J. Ame. Coll.
Cardiol. (2007) 50: 2173-95.
(5) Neri M, Riezzo I, Pascale N, Pomara C and
Turillazzi E. Ischemia/reperfusion injury following
acute myocardial infarction: a critical issue for
clinicians and forensic pathologists. Med. Inflamm.
(2017) 2017:
(6) Li X, Liu M, Sun R, Zeng Y, Chen S and Zhang P.
Protective approaches against myocardial ischemia
reperfusion injury. Exp. Ther Med. (2016) 12:
3823-9.
(7) Rahel BM, Visseren FL, Suttorp M-J, Plokker
TH, Kelder JC, de Jongh BM, Bouter KP and
Diepersloot RJ. Preprocedural serum levels
of acute-phase reactants and prognosis after
percutaneous coronary intervention. Cardiovasc.
Res. (2003) 60: 136-40.
(8) Monastero RN and Pentyala S. Cytokines as
biomarkers and their respective clinical cutoff
levels. Int. J. Inflamm. (2017) 2017.
(9) Nakashyan V, Tipton D, Karydis A, Livada R and
Stein S. Effect of 1, 25 (OH) 2D3 and 20 (OH) D3
on interleukin-1β-stimulated interleukin-6 and8 production by human gingival fibroblasts. J.
Periodontal. Res. (2017) 52: 832-41.
(10) Pelham CJ, Drews EM and Agrawal DK. Vitamin
D controls resistance artery function through
regulation of perivascular adipose tissue hypoxia
and inflammation. J. Mol. Cell Cardiol. (2016) 98:
1-10.
(11) Aslanabadi N, Jafaripor I, Sadeghi S, Hamishehkar
H, Ghaffari S, Toluey M, Azizi H and Entezari‐
Maleki T. Effect of vitamin D in the prevention of
myocardial injury following elective percutaneous
coronary intervention: A pilot randomized clinical
trial. J. Clin. Pharm. (2018) 58: 144-51.
(12) Thygesen K, Alpert JS, White HD, Katus HA,
Newby LK and Ravkilde J. Expert consensus
document. Circulation (2007) 116: 2634-53.
(13) Vlachopoulos C, Xaplanteris P, Aboyans V,
Brodmann M, Cífková R, Cosentino F, De Carlo
M, Gallino A, Landmesser U and Laurent S.
The role of vascular biomarkers for primary and
secondary prevention. A position paper from the
European Society of Cardiology Working Group on
peripheral circulation: Endorsed by the Association
for Research into Arterial Structure and Physiology
(ARTERY) Society. Atherosclerosis (2015) 241:
507-32.
(14) Ahmed M, Chowdhury NA, Rahman A, Rahman
M, Amin MG, Jannat S and Mollah RI. Elevated
Plasma High Sensitivity C-reactive Protein (hsCRP) Level is a Predictor of Periprocedural
Myocardial Injury during Percutaneous Coronary
Intervention (PCI). Bangladesh Heart J. (2015) 30:
5-12.
(15) Jones D and Patel J. Therapeutic approaches
targeting inflammation in cardiovascular disorders.
Biology (2018) 7: 49.
(16) Lee B-K, Koo B-K, Nam C-W, Doh J-H, Chung
W-Y, Cho B-R and Fearon WF. Does pre-treatment
with high dose atorvastatin prevent microvascular
dysfunction after percutaneous coronary
intervention in patients with acute coronary
syndrome? Korean Circ. J. (2016) 46: 472-80.
(17) Li L, Liu Q-W, Li Z, Wang L, Wang J-H, Song L
and Li B. The utility of high-sensitivity C-reactive
protein levels in patients with moderate coronary
lesions and gray-zone fractional flow reserve.
Anatol. J. Car. (2018) 20: 143.
(18) Wada H, Dohi T, Miyauchi K, Shitara J, Endo H,
Doi S, Naito R, Konishi H, Tsuboi S and Ogita M. 
290
Effect of Calcitriol on the IR Injury and Inflammation in PCI
Preprocedural high-sensitivity C-reactive protein
predicts long-term outcome of percutaneous
coronary intervention. Circ. J. (2016) 81: 90-5.
(19) Liuzzo G, Pedicino D, Flego D and Crea F.
Inflammation and Atherothrombosis, in Clinical
Immunology. Elsevier (2019)935-46.
(20) Mahesh NK, Sharma P, Gupta A, Bhat KG and
Verma N. Markers of inflammation following
percutaneous coronary intervention (PCI) and its
effect on adverse events. Int. J. Adv. Med. (2018) 5:
312-5.
(21) Reklou A, Doumas M, Imprialos K, Stavropoulos
K, Patoulias D and Athyros VG. Reduction of
Vascular Inflammation, LDL-C, or Both for the
Protection from Cardiovascular Events? Open
Cardiovasc. Med. J. (2018) 12: 29.
(22) Held C, White HD, Stewart RA, Budaj A, Cannon
CP, Hochman JS, Koenig W, Siegbahn A, Steg
PG and Soffer J. Inflammatory biomarkers
interleukin-6 and C-reactive protein and outcomes
in stable coronary heart disease: experiences from
the STABILITY (stabilization of atherosclerotic
plaque by initiation of darapladib therapy) trial. J.
Am. Heart Assoc. (2017) 6: e005077.
(23) Dastan F, Talasaz AH, Mojtahedzadeh M, Karimi
A, Salehiomran A, Bina P and Jalali A. Randomized
trial of carnitine for the prevention of perioperative
atrial fibrillation. in Seminars in thoracic and
cardiovascular Ssurgery, Elsevier (2018).
(24) Dastan F, Talasaz AH, Mojtahedzadeh M, Karimi
A, Salehiomran A, Bina P, Jalali A and Aghaie Z.
Potential effect of L-carnitine on the prevention
of myocardial injury after coronary artery bypass
graft surgery. J. Tehran University Heart Cen.
(2015) 10: 74.
(25) Thim T, Johansen MB, Chisholm GE, Schmidt M,
Kaltoft A, Sørensen HT, Thuesen L, Kristensen
SD, Bøtker HE and Krusell LR. Clopidogrel discontinuation within the first year after coronary
drug-eluting stent 030GF G0G0F G0 G0FG0F0GFG0GFF0G0GF0GHF0FGF0H0FG0GF0GF0GF0GTFGTHH0(2014) 14: 100.
(26) Zhou H, Ma Q, Zhu P, Ren J, Reiter RJ and Chen
Y. Protective role of melatonin in cardiac ischemia‐
reperfusion injury: From pathogenesis to targeted
therapy. J. Pineal Res. (2018) 64: e12471.